Exelixis (EXEL)
(Delayed Data from NSDQ)
$29.35 USD
+0.85 (2.98%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.38 +0.03 (0.10%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.35 USD
+0.85 (2.98%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.38 +0.03 (0.10%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Zacks News
Atara Biotherapeutics (ATRA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 65.93% and 483.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stocks' Q2 Earnings on Aug 9: EXEL, BHC & More
by Kinjel Shah
Let us look at four drug and biotech companies, EXEL, BHC, CPRX and AXSM, which are gearing up for their earnings release.
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -5.81% and 68.17%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 11.54% and 17.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exelixis (EXEL) to Post Q2 Earnings: What is in the Cards?
by Zacks Equity Research
Investors will likely focus on the demand for Cabometyx and pipeline updates when Exelixis (EXEL) reports Q2 results. Operating expenses might have jumped.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Exelixis (EXEL) Cabometyx Combo Study Meets Primary Goal
by Zacks Equity Research
Exelixis'(EXEL) late-stage study evaluating the combination of Cabometyx and Opdivo and Yervoy demonstrates significant improvement in progression-free survival at the primary analysis.
Exelixis (EXEL) Collaborates With Ryvu for Cancer Therapies
by Zacks Equity Research
Exelixis (EXEL) teams up with Ryvu Therapeutics to develop novel STING agonist-based targeted cancer therapies.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Exelixis (EXEL) Outperforms Industry in 1H22: What Lies Ahead?
by Zacks Equity Research
Exelixis (EXEL) outperforms the industry in the year so far on Cabometyx performance and pipeline progress.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Exelixis (EXEL) Begins Study on XL092 Combo in Colorectal Cancer
by Zacks Equity Research
Exelixis (EXEL) starts the phase III STELLAR-303 study evaluating XL092 in combination with atezolizumab as compared to regorafenib for treating patients with metastatic colorectal cancer.
Exelixis (EXEL), BioInvent Tie Up for Immuno-Oncology Therapies
by Zacks Equity Research
Exelixis (EXEL) looks to expand its biotherapeutics development pipeline by using BioInvent's proprietary immuno-oncology screening platform and antibody library.
Why Is Exelixis (EXEL) Down 3.1% Since Last Earnings Report?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exelixis (EXEL) Announces Results From Phase II HNSCC Study
by Zacks Equity Research
Exelixis (EXEL) phase II study evaluating Cabometyx in combination with Keytruda in patients with recurrent or metastatic head and neck squamous cell carcinoma meets primary goal.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Exelixis (EXEL) Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Exelixis (EXEL) beats on earnings but misses on revenues in the first quarter. While the top line increases on a year-over-year basis, the bottom line improves from the year-ago breakeven figure.
Exelixis (EXEL) Tops Q1 Earnings Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 50% and 6.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More
by Kanishka Das
Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.
Why Exelixis (EXEL) Might Surprise This Earnings Season
by Zacks Equity Research
Exelixis (EXEL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT